Critical Pharmacodynamic Warning

atomoxetine weakly inhibits the 2C19 metabolic pathway.

When patients take atomoxetine concurrently with drugs metabolized by 2C19, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.

Clinical Impact: As a weak inhibitor, atomoxetine can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.

Clinical Overview for atomoxetine

This page outlines known interaction pathways involving atomoxetine, focusing primarily on its profile as a Weak inhibitor affecting the 2C19 pathway.

Enzyme Interaction Profile

atomoxetine demonstrates weak inhibitor potency against 2C19. This level of inhibition causes ≥1.25-fold but <2-fold increase in AUC of substrate drugs.

Inhibitor

A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.

Clinical Example: atomoxetine weakly inhibits 2C19

Inducer

A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.

Known Inducers: letermovir
Interaction Details
Drug Name atomoxetine
Affected Enzyme 2C19
Inhibitor Strength Weak inhibitor Low Severity
Inducers letermovir
Inhibitors citalopram
Clinical Recommendations

Generally safe for co-administration. Routine monitoring recommended.

Monitoring Parameters:
  • Therapeutic drug levels
  • Adverse effect monitoring
  • Clinical response assessment
Dose Considerations:
  • Consider dose reduction
  • Evaluate alternative therapies
  • Adjust based on response
Quick Facts
Interaction ID
2267
Primary Pathway
2C19
Interaction Type
Enzyme Inhibition
Clinical Phase
Low Severity
Clinical Significance

Minor clinical significance. Routine monitoring sufficient.

Information Sources
  • FDA Drug Interaction Database
  • Clinical Pharmacology Guidelines
  • Pharmaceutical Labeling Information
  • Published Clinical Studies
Last updated: June 15, 2026
Back Return to Database